INTRODUCTION
Bacterial endotoxin or lipopolysaccharide (LPS) has been a principal focus for therapeutic efforts in septic shock research following the discovery that LPS is the major component of the outer membrane from Gramnegative bacteria that induces septic shock. [1] [2] [3] This complex macromolecule has amphipathic properties and possesses two phosphoric acid groups that are essential for full expression of its endotoxic potential. 4 Numerous endogenous and synthetic endotoxin binding molecules have been developed over the last several decades in efforts designed to block the injurious effects of endotoxin release within the systemic circulation in sepsis. 5 These anti-endotoxin therapies are clearly beneficial in many experimental models of sepsis, yet to date they have not lived up to their potential to be consistently protective in human sepsis. The search, therefore, continues with the ultimate goal of identifying a cost-effective, non-toxic and efficacious intervention strategy that will prevent the deleterious pathophysiological effects of endotoxemia in human disease.
The recent discovery that certain lipopolyamines used in DNA transfection experiments also have endotoxinbinding and neutralizing properties 6 prompted us to examine the potential therapeutic efficacy of these wellcharacterized molecules in an experimental animal infection model that very closely approximates systemic Gram-negative bacterial infection in humans resulting from Pseudomonas aeruginosa. 5 One lipopolyamine, known as DOSPER (1,3-di-oleoyloxy-2-(6-carboxylspermyl)-propylamide) was chosen for further study based upon its favorable toxicity profile, and optimal LPS binding characteristics. 6 The results described herein demonstrate the therapeutic activity of DOSPER in an animal model designed to mimic that sequence of events that lead to bacteremic infections in the neutropenic host.
Lipopolyamines are a class of polycationic amphiphilic compounds that have been shown to bind with high affinity to polyanionic macromolecules, including both DNA and bacterial lipopolysaccharide (LPS). One of these compounds, termed DOSPER (1,3-di-oleoyloxy-2-(6-carboxylspermyl)-propylamide), is non-cytotoxic and has been shown to inhibit LPS-mediated cytokine release and lethality in endotoxin challenge models. In the study reported here, the activity of DOSPER was tested in neutropenic rats with invasive Gram-negative bacteremia caused by Pseudomonas aeruginosa. DOSPER alone was ineffective (0/8) at influencing mortality, but provided a significant survival advantage if administered in combination with a bactericidal antibiotic, ceftazidime (10/12; P <0.05). Ceftazidime alone was partially protective (6/12) while the control group had no survivors (0/8). DOSPER administration markedly reduced circulating endotoxin levels (P <0.01) and interleukin-6 levels (P <0.05) but had no significant effect on bacteremia and bacterial concentrations of P. aeruginosa in liver or spleen tissue. Lipopolyamines may be potentially valuable as a therapeutic adjunct in treatment of Gram-negative bacterial sepsis.
MATERIALS AND METHODS

Materials and reagents
DOSPER (1,3-di-oleoyloxy-2-(6-carboxyl-spermyl)-propylamide) was purchased from Boehringer Mannheim (Indianapolis, IA, USA) and the antibiotics cefamandole (Lilly & Co., Indianapolis, IA, USA) and ceftazidime (Glaxo-Wellcome, Research Triangle Park, NC, USA) were purchased from commercial sources. Cyclophosphamide was obtained from Bristol-Myers (Evansville, IN, USA) and Pseudomonas isolation agar used for primary isolation of P. aeruginosa from tissue samples was obtained from Difco (Detroit, MI, USA). All other reagents and chemicals were purchased from Sigma (St Louis, MO, USA).
Blood levels of endotoxin were measured by an automated turbidimetric Limulus amebocyte lysate assay (Associates of Cape Cod, Woods Hole, MA, USA). Serum was heated and diluted 1:100 before running the samples to remove potential inhibitors; therefore, the functional limit of detection for this assay in this study was 20 pg/ml. Interleukin-6 (IL-6) levels were determined by a commercially available immunoassay for rat IL-6 (Biosource International, Camarillo, CA, USA). The lower limit of detection of this assay for rat IL-6 is 46.9 pg/ml and the upper range is 3000 pg/ml.
Animal model
The neutropenic rat model used in these experiments has been described in detail in previous publications. 5 The protocol has been approved by the Brown University Animal Care and Use Committee, and conforms overall experimentally to the National Research Council animal care guidelines. Female, non-pregnant, specific pathogen-free Sprague-Dawley rats weighing 150-200 g were obtained from Charles River Laboratories (Wilmington, MA, USA). Prior to all experiments, blood samples were obtained from all animals and baseline cytokine, endotoxin, and blood cultures ascertained. Animals were then given cefamandole (100 mg/kg i.m.) to assist in alimentary colonization with the challenge strain of P. aeruginosa. Animals were then rendered neutropenic by cyclophosphamide (150 mg/kg i.p. at time 0, and 50 mg/kg i.p. at time 72 h) and the rats colonized with P. aeruginosa strain 12.4.4 (kindly provided by A. McManus, San Antonio, TX, USA) given orally at 10 6 CFU at time 0, 48, and 96 h. The challenge strain is a serum-resistant, bloodstream isolate that belongs to Fisher-Devlin-Gnabasik immunotype 6.
Infected animals were closely monitored by serial body temperature recordings using a non-contact, digital infrared thermometer (Horiba Instruments, Markson Sciences, Phoenix, AZ, USA). At the onset of fever (usually 5-6 days), animals were randomized into one of four groups: (i) saline control (n = 8); (ii) DOSPER (1.5 mg/kg i.v. x 1) alone (n = 8); (iii) ceftazidime (50 mg/kg i.m. q 12 h) alone (n = 12); and (iv) a combined treatment group with DOSPER and ceftazidime (n = 12). In preliminary experiments, the minimum inhibitory concentration (MIC) of ceftazidime to the challenge strain of P. aeruginosa was 0.25 µg/ml and the MIC was found to be unaffected by the presence of DOSPER in a range from 0.1-100 µg/ml. Blood samples were obtained at the onset of fever and again 24 h after the treatment randomization. All experimental manipulations with the animals were conducted under light CO 2 anesthesia to minimize stress to the animals.
Experimental animals were examined daily until resolution of fever and return of neutrophil counts (day 12 after the initial dose of cyclophosphamide). At the end of the experiment, all remaining animals were sacrificed and underwent necropsy examination with quantitative determination of liver and spleen tissues from each animal for the presence of the challenge strain of P. aeruginosa.
Statistical analysis
Differences in survival among the four experimental groups were analyzed by Kaplan-Meier survival plots and a generalized Wilcoxon test was used to evaluate significance of any difference in lethality among the various groups. Differences in circulating levels of IL-6 and LPS and concentrations of bacteria in CFU/mg of tissue were analyzed by a Kruskal-Wallis non-parametric analysis of variance test. A Dunn's multiple comparisons post-test was then performed to determine statistically significant differences between groups. A probability of <0.05 was considered significant.
RESULTS
The standard Kaplan-Meier survival analysis of the DOSPER-treated animals, ceftazidime-treated animals, and the control group is presented in Figure 1 . Differences in survival between the four groups were highly significant over the course of the 12 day experimental period. The DOSPER group alone did not provide any survival benefit (0/8) and did not differ from the control group (0/8). The ceftazidime-treated group, as anticipated, showed a 50% survival rate (6/12) and this was significantly improved over the control group (P <0.01). Importantly, however, the combination of therapy with DOSPER and ceftazidime provided the greatest survival benefit. A total of 83% (10/12) of the animals randomized to this group survived the study period (P <0.05).
Baseline serum endotoxin levels were low in all groups (median-58 pg/ml, range <20-83 pg/ml) and did not differ detectably prior to bacterial challenge. DOSPER alone, or in combination with the antibiotic ceftazidime, markedly reduced circulating endotoxin levels within 24 h of treatment compared to the ceftazidime alone group or the saline control group (Table  1) . IL-6 levels were highly variable, although compared to the other groups, serum levels of IL-6 were significantly lower following treatment with the combination of DOSPER and ceftazidime (P <0.05). Antimicrobial treatment was highly effective in the elimination of the challenge strain of P. aeruginosa in the presence or absence of DOSPER treatment. Quantitative levels of the infecting micro-organism from the liver and splenic tissues did not differ between these two organs; therefore, the results of these tissue colony counts were combined for each group of animals. The DOSPER-treated group tended to have somewhat higher bacterial counts in hepatic and splenic tissues than the saline control group but, given the level of variability among individual animals in each group, these differences did not achieve statistical significance (Table 1) .
DISCUSSION
The lipopolyamine compound DOSPER has been documented to manifest endotoxin-neutralizing properties and to protect D-galactosamine-treated mice from lethal endotoxin challenge and to potentiate antibiotic efficacy in Gram-negative Escherichia coli infected animals. 6 In the current experiments, DOSPER was shown to markedly reduce circulating endotoxin levels in bacterial sepsis, but it failed to provide protection from lethality unless combined with effective antimicrobial therapy. The combination of therapeutic doses of the potent βlactam antibiotic ceftazidime and the endotoxin inhibitor DOSPER provided optimal protection in neutropenic animals with Gram-negative bacterial sepsis. These results indicate that endotoxin blockade is not likely to be protective alone in the presence of invasive Gramnegative bacterial infection. Median values with 95% confidence intervals of blood samples for LPS and IL-6 obtained 24 h after the initiation of the treatment regimen. Two separate experiments were performed (20 animals/experiment) and the results were combined. Colony counts of liver and splenic tissue did not significantly differ within each treatment group; therefore, the results were combined. LPS, lipopolysaccharide; IL-6, interleukin-6; CI, confidence intervals *P <0.05 versus control; **P <0.01 versus control; ***P <0.0001 versus control.
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Conversely, antimicrobial agents alone clear microbial pathogens from the systemic circulation and reduced IL-6 levels but failed to prevent endotoxin release in these immunocompromised animals. Ceftazidime is a highly efficacious antimicrobial agent that has the potential, at least in vitro, to promote endotoxin release as the bactericidal process develops. 8 In the current study, we were unable to find evidence of excess systemic endotoxin release following ceftazidime therapy. Plasma levels of endotoxin did not differ in the group of animals that received ceftazidime alone or saline control in the absence of DOSPER. This is perhaps a consequence of the competing effects of antibiotic-mediated rapid bacterial clearance (lowering systemic endotoxin levels) and enhanced endotoxin release during bacteriolysis (increasing endotoxin levels) in this active infection model. Only the combination of bactericidal antimicrobial agents in combination with the endotoxin inhibitor provided optimal protection in the neutropenic host with Gram-negative sepsis.
The antibacterial actions of potent β-lactam antibiotics such as ceftazidime result in the release of considerable amounts of immunologically and biologically active endotoxin from Gram-negative bacteria. 8 The injurious effects of antibiotic-induced endotoxin release may be prevented by the simultaneous administration of an effective anti-endotoxin strategy. This synergistic treatment relationship has a clear therapeutic rationale in experimental studies, 5, 8 but it has been difficult to confirm this in actual human sepsis. 9 It is anticipated that introduction of potent, non-toxic endotoxinneutralizing agents into clinical use will permit a detailed investigation of this combination approach in humans.
A number of anti-endotoxin strategies are currently in advanced clinical development to treat septic patients. Bactericidal/permeability-increasing protein, polymyxin Bbound hemofiltration columns, polymyxin B-dextran conjugants, Lipid A antagonists, antibodies to CD14, and core glycolipid structures of endotoxin and a variety of other therapeutic approaches may well have potential clinical utility. 5, 10, 11 The lipopolyamines such as the DOSPER compound used in the current study have a number of favorable attributes that are worthy of their further consideration as anti-endotoxin agents. These chemically-defined, relatively simple compounds are stable, highly soluble, and non-cytotoxic. [12] [13] [14] They have already undergone extensive preclinical 6, 12 and clinical testing as DNA transfection delivery agents. 15 They may well prove to be cost-effective endotoxin neutralizing agents for future consideration in the prevention and/or treatment of endotoxin-induced clinical conditions, including Gram-negative sepsis.
